{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:13:47Z","timestamp":1793142827751,"version":"4.5.0"},"reference-count":197,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009991","name":"Department of Finance of Jilin Province","doi-asserted-by":"publisher","award":["2025scz55"],"award-info":[{"award-number":["2025scz55"]}],"id":[{"id":"10.13039\/501100009991","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009991","name":"Department of Finance of Jilin Province","doi-asserted-by":"publisher","award":["2024SCZ43"],"award-info":[{"award-number":["2024SCZ43"]}],"id":[{"id":"10.13039\/501100009991","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.phrs.2026.108192","type":"journal-article","created":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T16:32:48Z","timestamp":1776011568000},"page":"108192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Roles of peroxisome proliferator-activated receptors (PPARs) in pancreatic metabolic diseases"],"prefix":"10.1016","volume":"227","author":[{"given":"Xiaoping","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianglong","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.phrs.2026.108192_bib1","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nm.3159","article-title":"PPARgamma signaling and metabolism: the good, the bad and the future","volume":"19","author":"Ahmadian","year":"2013","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.phrs.2026.108192_bib2","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.3390\/cells9112367","article-title":"The role of PPARs in disease","volume":"9","author":"Wagner","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.phrs.2026.108192_bib3","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/978-3-030-11488-6_3","article-title":"Understanding peroxisome proliferator-activated receptors: from the structure to the regulatory actions on metabolism","volume":"1127","author":"Lamas Bervejillo","year":"2019","journal-title":"Adv. Exp. Med Biol."},{"issue":"8","key":"10.1016\/j.phrs.2026.108192_bib4","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.bbalip.2007.02.013","article-title":"PPARs and molecular mechanisms of transrepression","volume":"1771","author":"Ricote","year":"2007","journal-title":"Biochim Biophys. Acta"},{"issue":"2","key":"10.1016\/j.phrs.2026.108192_bib5","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/MPA.0000000000000472","article-title":"Translational insights into peroxisome proliferator-activated receptors in experimental acute pancreatitis","volume":"45","author":"Huang","year":"2016","journal-title":"Pancreas"},{"issue":"3","key":"10.1016\/j.phrs.2026.108192_bib6","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","article-title":"Molecular mechanism of PPARalpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease","volume":"62","author":"Pawlak","year":"2015","journal-title":"J. Hepatol."},{"issue":"37","key":"10.1016\/j.phrs.2026.108192_bib7","doi-asserted-by":"crossref","first-page":"28918","DOI":"10.1074\/jbc.M910350199","article-title":"Defect in peroxisome proliferator-activated receptor alpha-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting","volume":"275","author":"Hashimoto","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"52","key":"10.1016\/j.phrs.2026.108192_bib8","doi-asserted-by":"crossref","first-page":"50237","DOI":"10.1074\/jbc.M201208200","article-title":"Peroxisome proliferator-activated receptor alpha (PPARalpha) influences substrate utilization for hepatic glucose production","volume":"277","author":"Xu","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.phrs.2026.108192_bib9","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1210\/endo.137.1.8536636","article-title":"Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat","volume":"137","author":"Braissant","year":"1996","journal-title":"Endocrinology"},{"issue":"6","key":"10.1016\/j.phrs.2026.108192_bib10","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.2337\/db06-0016","article-title":"Peroxisome proliferator-activated receptor alpha improves pancreatic adaptation to insulin resistance in obese mice and reduces lipotoxicity in human islets","volume":"55","author":"Lalloyer","year":"2006","journal-title":"Diabetes"},{"issue":"8","key":"10.1016\/j.phrs.2026.108192_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.23802","article-title":"mTORC2 knockdown mediates lipid metabolism to alleviate hyperlipidemic pancreatitis through PPARalpha","volume":"38","author":"Wang","year":"2024","journal-title":"J. Biochem Mol. Toxicol."},{"issue":"Pt 5","key":"10.1016\/j.phrs.2026.108192_bib12","article-title":"The global perspective on peroxisome proliferator-activated receptor gamma (PPARgamma) in ectopic fat deposition: a review","volume":"253","author":"Qiu","year":"2023","journal-title":"Int J. Biol. Macromol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108192_bib13","doi-asserted-by":"crossref","first-page":"E560","DOI":"10.1152\/ajpendo.00561.2002","article-title":"Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma2 in the modulation of insulin secretion","volume":"286","author":"Lupi","year":"2004","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.phrs.2026.108192_bib14","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.surg.2012.02.004","article-title":"Peroxisome proliferator-activated receptor beta\/delta agonist GW0742 ameliorates cerulein- and taurocholate-induced acute pancreatitis in mice","volume":"152","author":"Paterniti","year":"2012","journal-title":"Surgery"},{"issue":"4","key":"10.1016\/j.phrs.2026.108192_bib15","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jhep.2020.04.025","article-title":"Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages(\u2729)","volume":"73","author":"Lefere","year":"2020","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.phrs.2026.108192_bib16","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00134-004-2180-1","article-title":"Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute pancreatitis induced by cerulein","volume":"30","author":"Cuzzocrea","year":"2004","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.phrs.2026.108192_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108391","article-title":"PPAR-gamma signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets","volume":"245","author":"Chen","year":"2023","journal-title":"Pharm. Ther."},{"issue":"1","key":"10.1016\/j.phrs.2026.108192_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-83815-4","article-title":"PPAR-gamma agonist mitigates intestinal barrier dysfunction and inflammation induced by Clostridioides difficile SlpA in vitro","volume":"14","author":"Noori","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2026.108192_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2021.153818","article-title":"Oleic acid alleviates LPS-induced acute kidney injury by restraining inflammation and oxidative stress via the Ras\/MAPKs\/PPAR-gamma signaling pathway","volume":"94","author":"Zhang","year":"2022","journal-title":"Phytomedicine"},{"issue":"2","key":"10.1016\/j.phrs.2026.108192_bib20","doi-asserted-by":"crossref","first-page":"5371","DOI":"10.1002\/j.2040-4603.2024.tb00294.x","article-title":"Pancreatic crosstalk in the disease setting: understanding the impact of exocrine disease on endocrine function","volume":"14","author":"Villaca","year":"2024","journal-title":"Compr. Physiol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108192_bib21","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.3390\/jcm13041179","article-title":"Interactions between the exocrine and the endocrine pancreas","volume":"13","author":"Valente","year":"2024","journal-title":"J. Clin. Med"},{"issue":"9","key":"10.1016\/j.phrs.2026.108192_bib22","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/j.1532-5415.1966.tb02854.x","article-title":"Aging and endocrine function--the pancreas","volume":"14","author":"Rosenberg","year":"1966","journal-title":"J. Am. Geriatr. Soc."},{"issue":"1","key":"10.1016\/j.phrs.2026.108192_bib23","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1017\/S0954422414000031","article-title":"Nutrient regulation of glucagon secretion: involvement in metabolism and diabetes","volume":"27","author":"Marroqui","year":"2014","journal-title":"Nutr. Res Rev."},{"issue":"18","key":"10.1016\/j.phrs.2026.108192_bib24","doi-asserted-by":"crossref","first-page":"9191","DOI":"10.3390\/ijms26189191","article-title":"The pivotal role of the western diet, hyperinsulinemia, ectopic fat, and diacylglycerol-mediated insulin resistance in type 2 diabetes","volume":"26","author":"Janssen","year":"2025","journal-title":"Int J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.phrs.2026.108192_bib25","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.3390\/cancers17111765","article-title":"Fatty pancreas: its potential as a risk factor for pancreatic cancer and clinical implications","volume":"17","author":"Otsuka","year":"2025","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.phrs.2026.108192_bib26","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41575-021-00551-0","article-title":"Intra-pancreatic fat deposition: bringing hidden fat to the fore","volume":"19","author":"Petrov","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108192_bib27","doi-asserted-by":"crossref","first-page":"6582","DOI":"10.1038\/s41598-024-57294-6","article-title":"Role of the fatty pancreatic infiltration in pancreatic oncogenesis","volume":"14","author":"Frendi","year":"2024","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.phrs.2026.108192_bib28","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/ajg.2014.1","article-title":"Fatty pancreas, insulin resistance, and beta-cell function: a population study using fat-water magnetic resonance imaging","volume":"109","author":"Wong","year":"2014","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.phrs.2026.108192_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.metabol.2016.12.012","article-title":"Ectopic fat accumulation in the pancreas and its clinical relevance: a systematic review, meta-analysis, and meta-regression","volume":"69","author":"Singh","year":"2017","journal-title":"Metabolism"},{"issue":"6","key":"10.1016\/j.phrs.2026.108192_bib30","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1097\/MPG.0b013e318244a685","article-title":"Increased pancreatic fat fraction is present in obese adolescents with metabolic syndrome","volume":"54","author":"Maggio","year":"2012","journal-title":"J. Pedia Gastroenterol. Nutr."},{"issue":"1","key":"10.1016\/j.phrs.2026.108192_bib31","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41574-021-00573-3","article-title":"Metabolic implications of pancreatic fat accumulation","volume":"18","author":"Wagner","year":"2022","journal-title":"Nat. Rev. Endocrinol."},{"issue":"6","key":"10.1016\/j.phrs.2026.108192_bib32","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.14309\/ajg.0000000000002792","article-title":"Associations of intrapancreatic fat deposition with incident diseases of the exocrine and endocrine pancreas: A UK biobank prospective cohort study","volume":"119","author":"Dong","year":"2024","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.phrs.2026.108192_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.103996","article-title":"Uniting epidemiology and experimental models: pancreatic steatosis and pancreatic cancer","volume":"79","author":"Truong","year":"2022","journal-title":"EBioMedicine"},{"issue":"5","key":"10.1016\/j.phrs.2026.108192_bib34","first-page":"408","article-title":"Chronic pancreatitis: evolution of the disease","volume":"38","author":"Kloppel","year":"1991","journal-title":"Hepatogastroenterology"},{"issue":"5","key":"10.1016\/j.phrs.2026.108192_bib35","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.gie.2011.01.015","article-title":"A prospective evaluation of fatty pancreas by using EUS","volume":"73","author":"Sepe","year":"2011","journal-title":"Gastrointest. Endosc."},{"issue":"5","key":"10.1016\/j.phrs.2026.108192_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0062561","article-title":"The association between nonalcoholic fatty pancreas disease and diabetes","volume":"8","author":"Ou","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.phrs.2026.108192_bib37","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrgastro.2011.4","article-title":"The clinical significance of pancreatic steatosis","volume":"8","author":"Smits","year":"2011","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108192_bib38","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s40265-024-02022-7","article-title":"The pharmacological landscape for fatty change of the pancreas","volume":"84","author":"Petrov","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2026.108192_bib39","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6629455","article-title":"PPAR-alpha agonist fenofibrate combined with octreotide acetate in the treatment of acute hyperlipidemia pancreatitis","volume":"2021","author":"Bao","year":"2021","journal-title":"PPAR Res"},{"issue":"4","key":"10.1016\/j.phrs.2026.108192_bib40","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/ajg.2009.27","article-title":"Hypertriglyceridemic pancreatitis: presentation and management","volume":"104","author":"Tsuang","year":"2009","journal-title":"Am. J. Gastroenterol."},{"issue":"18","key":"10.1016\/j.phrs.2026.108192_bib41","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.3748\/wjg.v29.i18.2747","article-title":"Current trends in acute pancreatitis: diagnostic and therapeutic challenges","volume":"29","author":"Zerem","year":"2023","journal-title":"World J. Gastroenterol."},{"issue":"8","key":"10.1016\/j.phrs.2026.108192_bib42","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41575-019-0158-2","article-title":"New insights into acute pancreatitis","volume":"16","author":"Lee","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"10249","key":"10.1016\/j.phrs.2026.108192_bib43","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0140-6736(20)31318-0","article-title":"Chronic pancreatitis","volume":"396","author":"Beyer","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.phrs.2026.108192_bib44","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0016-5085(98)70209-4","article-title":"Identification, culture, and characterization of pancreatic stellate cells in rats and humans","volume":"115","author":"Bachem","year":"1998","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.phrs.2026.108192_bib45","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1172\/JCI30082","article-title":"The pancreatic stellate cell: a star on the rise in pancreatic diseases","volume":"117","author":"Omary","year":"2007","journal-title":"J. Clin. Invest"},{"issue":"3","key":"10.1016\/j.phrs.2026.108192_bib46","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1097\/MPA.0b013e3181744b50","article-title":"Chronic high-fat diets induce oxide injuries and fibrogenesis of pancreatic cells in rats","volume":"37","author":"Zhang","year":"2008","journal-title":"Pancreas"},{"issue":"2","key":"10.1016\/j.phrs.2026.108192_bib47","doi-asserted-by":"crossref","first-page":"e569","DOI":"10.1210\/clinem\/dgaf623","article-title":"Approach to the patient with pancreatogenic diabetes","volume":"111","author":"Ode","year":"2026","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.phrs.2026.108192_bib48","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S2468-1253(16)30106-6","article-title":"Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer","volume":"1","author":"Hart","year":"2016","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"11","key":"10.1016\/j.phrs.2026.108192_bib49","doi-asserted-by":"crossref","DOI":"10.4240\/wjgs.v17.i11.112204","article-title":"Pancreatogenic diabetes: pathophysiology, diagnosis, and management challenges","volume":"17","author":"Wang","year":"2025","journal-title":"World J. Gastrointest. Surg."},{"issue":"D1","key":"10.1016\/j.phrs.2026.108192_bib50","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkae973","article-title":"Generic Diagramming Platform (GDP): a comprehensive database of high-quality biomedical graphics","volume":"53","author":"Jiang","year":"2025","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.phrs.2026.108192_bib51","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.biochi.2016.12.019","article-title":"The role and regulation of the peroxisome proliferator activated receptor alpha in human liver","volume":"136","author":"Kersten","year":"2017","journal-title":"Biochimie"},{"issue":"12","key":"10.1016\/j.phrs.2026.108192_bib52","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.2337\/diabetes.50.12.2809","article-title":"PPAR-alpha-null mice are protected from high-fat diet-induced insulin resistance","volume":"50","author":"Guerre-Millo","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.phrs.2026.108192_bib53","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ejmech.2019.01.067","article-title":"Role of PPAR receptor in different diseases and their ligands: physiological importance and clinical implications","volume":"166","author":"Mirza","year":"2019","journal-title":"Eur. J. Med Chem."},{"issue":"6","key":"10.1016\/j.phrs.2026.108192_bib54","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1586\/14779072.2014.904745","article-title":"Fibroblast growth factor 21: a promising therapeutic target in obesity-related diseases","volume":"12","author":"Cheung","year":"2014","journal-title":"Expert Rev. Cardiovasc Ther."},{"key":"10.1016\/j.phrs.2026.108192_bib55","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12986-019-0375-2","article-title":"Perilipin5 protects against lipotoxicity and alleviates endoplasmic reticulum stress in pancreatic beta-cells","volume":"16","author":"Zhu","year":"2019","journal-title":"Nutr. Metab. (Lond. )"},{"key":"10.1016\/j.phrs.2026.108192_bib56","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejphar.2018.09.015","article-title":"Selective peroxisome proliferator-activated receptor-alpha modulator K-877 regulates the expression of ATP-binding cassette transporter A1 in pancreatic beta cells","volume":"838","author":"Dong","year":"2018","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.phrs.2026.108192_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117494","article-title":"A new potent and selective peroxisome proliferator-activated receptor alpha partial agonist displays anti-steatotic effects In vitro and behaves as a safe hypolipidemic and hypoglycemic agent in a diabetic mouse model","volume":"289","author":"Laghezza","year":"2025","journal-title":"Eur. J. Med Chem."},{"issue":"2","key":"10.1016\/j.phrs.2026.108192_bib58","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1006\/bbrc.2000.2647","article-title":"Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight","volume":"271","author":"Chaput","year":"2000","journal-title":"Biochem Biophys. Res Commun."},{"issue":"9","key":"10.1016\/j.phrs.2026.108192_bib59","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.2337\/diabetes.52.9.2331","article-title":"Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation","volume":"52","author":"Koh","year":"2003","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.phrs.2026.108192_bib60","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0021-9150(96)05939-4","article-title":"Opposite effects of bezafibrate and gemfibrozil in both normal and hypertriglyceridemic rats","volume":"127","author":"Krause","year":"1996","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.phrs.2026.108192_bib61","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/00006676-200304000-00013","article-title":"Bezafibrate, a peroxisome proliferator-activated receptor (PPAR)-alpha activator, prevents pancreatic degeneration in obese and diabetic rats","volume":"26","author":"Jia","year":"2003","journal-title":"Pancreas"},{"issue":"5","key":"10.1016\/j.phrs.2026.108192_bib62","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1210\/er.2018-00064","article-title":"Molecular actions of PPARalpha in lipid metabolism and inflammation","volume":"39","author":"Bougarne","year":"2018","journal-title":"Endocr. Rev."},{"issue":"45","key":"10.1016\/j.phrs.2026.108192_bib63","doi-asserted-by":"crossref","first-page":"32048","DOI":"10.1074\/jbc.274.45.32048","article-title":"Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1","volume":"274","author":"Delerive","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.phrs.2026.108192_bib64","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1365-2567.2006.02393.x","article-title":"Role of peroxisome proliferator-activated receptor-alpha in acute pancreatitis induced by cerulein","volume":"118","author":"Genovese","year":"2006","journal-title":"Immunology"},{"issue":"1","key":"10.1016\/j.phrs.2026.108192_bib65","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/MPA.0b013e3182550cc4","article-title":"Attenuation of acute pancreatitis by peroxisome proliferator-activated receptor-alpha in rats: the effect on Toll-like receptor signaling pathways","volume":"42","author":"Ding","year":"2013","journal-title":"Pancreas"},{"issue":"21","key":"10.1016\/j.phrs.2026.108192_bib66","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJM197705262962101","article-title":"Gallbladder disease as a side effect of drugs influencing lipid metabolism. Experience in the Coronary Drug Project","volume":"296","author":"Coronary Drug Project Research","year":"1977","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.phrs.2026.108192_bib67","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1365-2362.1984.tb02105.x","article-title":"Effect of short-term treatment with bezafibrate and fenofibrate on biliary lipid metabolism in patients with hyperlipoproteinaemia","volume":"14","author":"von Bergmann","year":"1984","journal-title":"Eur. J. Clin. Invest"},{"issue":"8","key":"10.1016\/j.phrs.2026.108192_bib68","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1001\/jama.2012.8439","article-title":"Lipid-modifying therapies and risk of pancreatitis: a meta-analysis","volume":"308","author":"Preiss","year":"2012","journal-title":"JAMA"},{"issue":"21-22","key":"10.1016\/j.phrs.2026.108192_bib69","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/j.cca.2010.08.003","article-title":"Triglycerides and gallstone formation","volume":"411","author":"Smelt","year":"2010","journal-title":"Clin. Chim. Acta"},{"issue":"2","key":"10.1016\/j.phrs.2026.108192_bib70","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1113\/expphysiol.2012.068734","article-title":"Overexpression of peroxisome proliferator-activated receptor alpha in pancreatic beta-cells improves glucose tolerance in diet-induced obese mice","volume":"98","author":"Hogh","year":"2013","journal-title":"Exp. Physiol."},{"issue":"12","key":"10.1016\/j.phrs.2026.108192_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2024.100692","article-title":"Lipotoxicity of palmitic acid is associated with DGAT1 downregulation and abolished by PPARalpha activation in liver cells","volume":"65","author":"Moliterni","year":"2024","journal-title":"J. Lipid Res"},{"issue":"11","key":"10.1016\/j.phrs.2026.108192_bib72","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/j.febslet.2005.03.020","article-title":"Pancreatic islet response to hyperglycemia is dependent on peroxisome proliferator-activated receptor alpha (PPARalpha)","volume":"579","author":"Bihan","year":"2005","journal-title":"FEBS Lett."},{"issue":"3","key":"10.1016\/j.phrs.2026.108192_bib73","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1172\/JCI27989","article-title":"Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis","volume":"116","author":"Lefebvre","year":"2006","journal-title":"J. Clin. Invest"},{"issue":"11","key":"10.1016\/j.phrs.2026.108192_bib74","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1136\/gutjnl-2020-321774","article-title":"Hepatic Kruppel-like factor 16 (KLF16) targets PPARalpha to improve steatohepatitis and insulin resistance","volume":"70","author":"Sun","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.phrs.2026.108192_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118868","article-title":"Aerobic training improves NAFLD markers and insulin resistance through AMPK-PPAR-alpha signaling in obese mice","volume":"266","author":"Diniz","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.phrs.2026.108192_bib76","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.metabol.2017.02.013","article-title":"Renoprotective effect of a novel selective PPARalpha modulator K-877 in db\/db mice: A role of diacylglycerol-protein kinase C-NAD(P)H oxidase pathway","volume":"71","author":"Maki","year":"2017","journal-title":"Metabolism"},{"issue":"2","key":"10.1016\/j.phrs.2026.108192_bib77","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.orcp.2016.03.012","article-title":"Fish oil and fenofibrate inhibit pancreatic islet hypertrophy, and improve glucose and lipid metabolic dysfuntions with different ways in diabetic KK mice","volume":"12","author":"Nakasatomi","year":"2018","journal-title":"Obes. Res Clin. Pr."},{"key":"10.1016\/j.phrs.2026.108192_bib78","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.metabol.2017.09.001","article-title":"Fenofibrate attenuates fatty acid-induced islet beta-cell dysfunction and apoptosis via inhibiting the NF-kappaB\/MIF dependent inflammatory pathway","volume":"77","author":"Zheng","year":"2017","journal-title":"Metabolism"},{"issue":"12","key":"10.1016\/j.phrs.2026.108192_bib79","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1007\/s00125-019-04973-z","article-title":"Fenofibrate increases very-long-chain sphingolipids and improves blood glucose homeostasis in NOD mice","volume":"62","author":"Holm","year":"2019","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.phrs.2026.108192_bib80","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1210\/en.2007-1275","article-title":"Peroxisome proliferator-activated receptor-alpha regulates the expression of pancreatic\/duodenal homeobox-1 in rat insulinoma (INS-1) cells and ameliorates glucose-induced insulin secretion impaired by palmitate","volume":"149","author":"Sun","year":"2008","journal-title":"Endocrinology"},{"issue":"5","key":"10.1016\/j.phrs.2026.108192_bib81","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1159\/000106485","article-title":"Peroxisome proliferator-activated receptor-alpha deficiency protects aged mice from insulin resistance induced by high-fat diet","volume":"27","author":"Cha","year":"2007","journal-title":"Am. J. Nephrol."},{"issue":"2","key":"10.1016\/j.phrs.2026.108192_bib82","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.bbadis.2004.11.011","article-title":"Roles of PPAR delta in lipid absorption and metabolism: a new target for the treatment of type 2 diabetes","volume":"1740","author":"Luquet","year":"2005","journal-title":"Biochim Biophys. Acta"},{"issue":"9","key":"10.1016\/j.phrs.2026.108192_bib83","doi-asserted-by":"crossref","first-page":"5306","DOI":"10.1073\/pnas.091021198","article-title":"A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport","volume":"98","author":"Oliver","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.phrs.2026.108192_bib84","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.cellsig.2013.11.019","article-title":"Activation of PPARbeta\/delta protects pancreatic beta cells from palmitate-induced apoptosis by upregulating the expression of GLP-1 receptor","volume":"26","author":"Yang","year":"2014","journal-title":"Cell Signal"},{"issue":"3","key":"10.1016\/j.phrs.2026.108192_bib85","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.bbrc.2009.12.127","article-title":"Activation of PPARdelta up-regulates fatty acid oxidation and energy uncoupling genes of mitochondria and reduces palmitate-induced apoptosis in pancreatic beta-cells","volume":"391","author":"Wan","year":"2010","journal-title":"Biochem Biophys. Res Commun."},{"issue":"10","key":"10.1016\/j.phrs.2026.108192_bib86","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/lipd.12182","article-title":"Activated PPARbeta\/delta protects pancreatic beta cells in type 2 Diabetic Goto-Kakizaki rats from lipoapoptosis via GPR40","volume":"54","author":"Li","year":"2019","journal-title":"Lipids"},{"issue":"8","key":"10.1016\/j.phrs.2026.108192_bib87","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.bbalip.2007.03.006","article-title":"PPARgamma in human and mouse physiology","volume":"1771","author":"Heikkinen","year":"2007","journal-title":"Biochim Biophys. Acta"},{"issue":"12 Pt A","key":"10.1016\/j.phrs.2026.108192_bib88","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/j.bbalip.2016.09.010","article-title":"PPARgamma regulates exocrine pancreas lipase","volume":"1861","author":"Danino","year":"2016","journal-title":"Biochim Biophys. Acta"},{"issue":"19","key":"10.1016\/j.phrs.2026.108192_bib89","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1042\/CS20190093","article-title":"Fibroblast growth factor 21 protects against lipotoxicity-induced pancreatic beta-cell dysfunction via regulation of AMPK signaling and lipid metabolism","volume":"133","author":"Xie","year":"2019","journal-title":"Clin. Sci."},{"key":"10.1016\/j.phrs.2026.108192_bib90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mce.2015.05.014","article-title":"Fetuin A promotes lipotoxicity in beta cells through the TLR4 signaling pathway and the role of pioglitazone in anti-lipotoxicity","volume":"412","author":"Shen","year":"2015","journal-title":"Mol. Cell Endocrinol."},{"issue":"5","key":"10.1016\/j.phrs.2026.108192_bib91","doi-asserted-by":"crossref","first-page":"R1332","DOI":"10.1152\/ajpregu.2001.280.5.R1332","article-title":"Troglitazone stimulates pancreatic growth in congenitally CCK-A receptor-deficient OLETF rats","volume":"280","author":"Jia","year":"2001","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"issue":"5","key":"10.1016\/j.phrs.2026.108192_bib92","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/MPA.0b013e3182153922","article-title":"Pancreatic ultrastructural enhancement due to telmisartan plus sitagliptin treatment in diet-induced obese C57BL\/6 mice","volume":"40","author":"Souza-Mello","year":"2011","journal-title":"Pancreas"},{"issue":"1","key":"10.1016\/j.phrs.2026.108192_bib93","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s10753-021-01527-7","article-title":"Diallyl Disulfide Attenuates STAT3 and NF-kappaB Pathway Through PPAR-gamma Activation in Cerulein-Induced Acute Pancreatitis and Associated Lung Injury in Mice","volume":"45","author":"Marimuthu","year":"2022","journal-title":"Inflammation"},{"issue":"2","key":"10.1016\/j.phrs.2026.108192_bib94","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1007\/s00125-014-3438-y","article-title":"Genetic deletion of Wdr13 improves the metabolic phenotype of Lepr (db\/db) mice by modulating AP1 and PPARgamma target genes","volume":"58","author":"Singh","year":"2015","journal-title":"Diabetologia"},{"issue":"7","key":"10.1016\/j.phrs.2026.108192_bib95","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1344","article-title":"Low-dose decitabine promotes M2 macrophage polarization in patients with primary immune thrombocytopenia via enhancing KLF4 binding to PPARgamma promoter","volume":"13","author":"Shao","year":"2023","journal-title":"Clin. Transl. Med."},{"issue":"4","key":"10.1016\/j.phrs.2026.108192_bib96","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3892\/ijmm.2023.5298","article-title":"Adropin attenuates pancreatitis\u2011associated lung injury through PPARgamma phosphorylation\u2011related macrophage polarization","volume":"52","author":"Ding","year":"2023","journal-title":"Int J. Mol. Med"},{"issue":"4","key":"10.1016\/j.phrs.2026.108192_bib97","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3892\/mmr.2022.12818","article-title":"Lutein inhibits IL\u20116 expression by inducing PPAR\u2011gamma activation and SOCS3 expression in cerulein\u2011stimulated pancreatic acinar cells","volume":"26","author":"Ahn","year":"2022","journal-title":"Mol. Med Rep."},{"issue":"2","key":"10.1016\/j.phrs.2026.108192_bib98","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.arcmed.2008.11.004","article-title":"Rosiglitazone attenuates the severity of sodium taurocholate-induced acute pancreatitis and pancreatitis-associated lung injury","volume":"40","author":"Chen","year":"2009","journal-title":"Arch. Med. Res."},{"issue":"4","key":"10.1016\/j.phrs.2026.108192_bib99","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.biocel.2007.10.007","article-title":"SOCS 3 and PPAR-gamma ligands inhibit the expression of IL-6 and TGF-beta1 by regulating JAK2\/STAT3 signaling in pancreas","volume":"40","author":"Yu","year":"2008","journal-title":"Int J. Biochem Cell Biol."},{"issue":"2","key":"10.1016\/j.phrs.2026.108192_bib100","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.trsl.2012.02.003","article-title":"Pioglitazone, a PPAR-gamma activator, attenuates the severity of cerulein-induced acute pancreatitis by modulating early growth response-1 transcription factor","volume":"160","author":"Wan","year":"2012","journal-title":"Transl. Res"},{"issue":"40","key":"10.1016\/j.phrs.2026.108192_bib101","doi-asserted-by":"crossref","first-page":"6322","DOI":"10.3748\/wjg.v11.i40.6322","article-title":"Pioglitazone, a specific ligand of peroxisome proliferator-activated receptor-gamma, protects pancreas against acute cerulein-induced pancreatitis","volume":"11","author":"Konturek","year":"2005","journal-title":"World J. Gastroenterol."},{"issue":"13","key":"10.1016\/j.phrs.2026.108192_bib102","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.3748\/wjg.v13.i13.1983","article-title":"Pioglitazone attenuates the severity of sodium taurocholate-induced severe acute pancreatitis","volume":"13","author":"Xu","year":"2007","journal-title":"World J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108192_bib103","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1007\/s10620-010-1393-0","article-title":"Pioglitazone: a promising therapeutic tool in sodium taurocholate-induced severe acute pancreatitis","volume":"56","author":"Xu","year":"2011","journal-title":"Dig. Dis. Sci."},{"issue":"7","key":"10.1016\/j.phrs.2026.108192_bib104","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.biopha.2007.10.012","article-title":"Pioglitazone, a PPARgamma ligand, suppresses NFkappaB activation through inhibition of IkappaB kinase activation in cerulein-treated AR42J cells","volume":"62","author":"Wan","year":"2008","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.phrs.2026.108192_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106786","article-title":"Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD)","volume":"192","author":"Qiu","year":"2023","journal-title":"Pharm. Res"},{"issue":"1","key":"10.1016\/j.phrs.2026.108192_bib106","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nm.2277","article-title":"Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin","volume":"17","author":"Holland","year":"2011","journal-title":"Nat. Med"},{"key":"10.1016\/j.phrs.2026.108192_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2023.101821","article-title":"Protective roles of adiponectin and molecular signatures of HNF4alpha and PPARalpha as downstream targets of adiponectin in pancreatic beta cells","volume":"78","author":"Onodera","year":"2023","journal-title":"Mol. Metab."},{"issue":"6","key":"10.1016\/j.phrs.2026.108192_bib108","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/cbf.1684","article-title":"Concurrently using rosiglitazone prevents glucosamine-induced islet beta-cell apoptosis and dysfunction","volume":"28","author":"Zhang","year":"2010","journal-title":"Cell Biochem Funct."},{"issue":"2","key":"10.1016\/j.phrs.2026.108192_bib109","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1210\/me.2011-1181","article-title":"PPAR-gamma activation restores pancreatic islet SERCA2 levels and prevents beta-cell dysfunction under conditions of hyperglycemic and cytokine stress","volume":"26","author":"Kono","year":"2012","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.phrs.2026.108192_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.115183","article-title":"PPARgamma activation reduces pancreatic beta cell death in type 1 diabetes by decreasing heparanase-dependent insulitis","volume":"162","author":"Zhou","year":"2025","journal-title":"Int. Immunopharmacol."},{"issue":"7","key":"10.1016\/j.phrs.2026.108192_bib111","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/j.1463-1326.2007.00749.x","article-title":"Pioglitazone attenuates fatty acid-induced oxidative stress and apoptosis in pancreatic beta-cells","volume":"10","author":"Saitoh","year":"2008","journal-title":"Diabetes Obes. Metab."},{"issue":"10","key":"10.1016\/j.phrs.2026.108192_bib112","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1210\/en.2014-1076","article-title":"Overexpression of PPARgamma specifically in pancreatic beta-cells exacerbates obesity-induced glucose intolerance, reduces beta-cell mass, and alters islet lipid metabolism in male mice","volume":"155","author":"Hogh","year":"2014","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.phrs.2026.108192_bib113","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.bbrc.2004.08.238","article-title":"PPAR-gamma overexpression selectively suppresses insulin secretory capacity in isolated pancreatic islets through induction of UCP-2 protein","volume":"324","author":"Ito","year":"2004","journal-title":"Biochem Biophys. Res. Commun."},{"issue":"32","key":"10.1016\/j.phrs.2026.108192_bib114","first-page":"20230","article-title":"Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPARgamma)","volume":"272","author":"Werman","year":"1997","journal-title":"Differ. Act. PPARgamma1 -2 isoforms Influ. Insul. J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.phrs.2026.108192_bib115","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00535-009-0013-2","article-title":"Signal transduction in pancreatic stellate cells","volume":"44","author":"Masamune","year":"2009","journal-title":"J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108192_bib116","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1074\/jbc.M107582200","article-title":"Ligands of peroxisome proliferator-activated receptor-gamma block activation of pancreatic stellate cells","volume":"277","author":"Masamune","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.phrs.2026.108192_bib117","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/j.1582-4934.2005.tb00497.x","article-title":"Peroxisome proliferator-activated receptor gamma overexpression inhibits pro-fibrogenic activities of immortalised rat pancreatic stellate cells","volume":"9","author":"Jaster","year":"2005","journal-title":"J. Cell Mol. Med."},{"issue":"2","key":"10.1016\/j.phrs.2026.108192_bib118","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/00006676-200203000-00010","article-title":"Thiazolidinedione derivatives as novel therapeutic agents to prevent the development of chronic pancreatitis","volume":"24","author":"Shimizu","year":"2002","journal-title":"Pancreas"},{"issue":"3","key":"10.1016\/j.phrs.2026.108192_bib119","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0002-9440(10)62293-6","article-title":"Therapeutic effects of troglitazone in experimental chronic pancreatitis in mice","volume":"166","author":"van Westerloo","year":"2005","journal-title":"Am. J. Pathol."},{"issue":"2","key":"10.1016\/j.phrs.2026.108192_bib120","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0092-8674(03)00269-1","article-title":"Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity","volume":"113","author":"Wang","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2026.108192_bib121","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.metabol.2017.04.005","article-title":"Macrophage functions in lean and obese adipose tissue","volume":"72","author":"Thomas","year":"2017","journal-title":"Metabolism"},{"key":"10.1016\/j.phrs.2026.108192_bib122","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13578-020-00450-y","article-title":"Macrophages inhibit adipogenic differentiation of adipose tissue derived mesenchymal stem\/stromal cells by producing pro-inflammatory cytokines","volume":"10","author":"Ma","year":"2020","journal-title":"Cell Biosci."},{"issue":"2","key":"10.1016\/j.phrs.2026.108192_bib123","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2023.2265939","article-title":"Comprehensive review on the pathogenesis of hypertriglyceridaemia-associated acute pancreatitis","volume":"55","author":"Qiu","year":"2023","journal-title":"Ann. Med"},{"issue":"5","key":"10.1016\/j.phrs.2026.108192_bib124","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1161\/01.HYP.0000187900.36455.4c","article-title":"Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor-alpha activators","volume":"46","author":"Han","year":"2005","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.phrs.2026.108192_bib125","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1046\/j.1463-1326.2002.00199.x","article-title":"Effects of gemfibrozil on insulin resistance to fat metabolism in subjects with type 2 diabetes and hypertriglyceridaemia","volume":"4","author":"Whitelaw","year":"2002","journal-title":"Diabetes Obes. Metab."},{"issue":"3","key":"10.1016\/j.phrs.2026.108192_bib126","doi-asserted-by":"crossref","first-page":"538","DOI":"10.2337\/dc17-1589","article-title":"Effects of pemafibrate, a novel selective PPARalpha modulator, on lipid and glucose metabolism in patients with type 2 diabetes and hypertriglyceridemia: a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"41","author":"Araki","year":"2018","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.phrs.2026.108192_bib127","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.3390\/pharmaceutics15071838","article-title":"Favorable effect of pemafibrate on insulin resistance and beta-cell function in subjects with type 2 diabetes and hypertriglyceridemia: a subanalysis of the PARM-T2D Study","volume":"15","author":"Nomoto","year":"2023","journal-title":"Pharmaceutics"},{"issue":"9","key":"10.1016\/j.phrs.2026.108192_bib128","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1038\/sj.ki.5000209","article-title":"PPARalpha agonist fenofibrate improves diabetic nephropathy in db\/db mice","volume":"69","author":"Park","year":"2006","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.phrs.2026.108192_bib129","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1055\/s-0043-121143","article-title":"PPAR-alpha agonist improves hyperglycemia-induced oxidative stress in pancreatic cells by potentiating antioxidant defense system","volume":"68","author":"Yaribeygi","year":"2018","journal-title":"Drug Res."},{"issue":"3","key":"10.1016\/j.phrs.2026.108192_bib130","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jdiacomp.2014.01.001","article-title":"The peroxisome proliferator-activated receptor alpha agonist fenofibrate has no effect on insulin sensitivity compared to atorvastatin in type 2 diabetes mellitus; a randomised, double-blind controlled trial","volume":"28","author":"Black","year":"2014","journal-title":"J. Diabetes Complicat."},{"issue":"5","key":"10.1016\/j.phrs.2026.108192_bib131","doi-asserted-by":"crossref","first-page":"579","DOI":"10.33549\/physiolres.931058","article-title":"Influence of PPAR-alpha agonist fenofibrate on insulin sensitivity and selected adipose tissue-derived hormones in obese women with type 2 diabetes","volume":"56","author":"Anderlova","year":"2007","journal-title":"Physiol. Res"},{"issue":"8","key":"10.1016\/j.phrs.2026.108192_bib132","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s00125-007-0698-9","article-title":"Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus","volume":"50","author":"Bajaj","year":"2007","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.phrs.2026.108192_bib133","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2337\/db07-1318","article-title":"Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men","volume":"57","author":"Riserus","year":"2008","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.phrs.2026.108192_bib134","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/sj.bjp.0707452","article-title":"Thiazolidinediones: effects on insulin resistance and the cardiovascular system","volume":"153","author":"Quinn","year":"2008","journal-title":"Br. J. Pharm."},{"issue":"12","key":"10.1016\/j.phrs.2026.108192_bib135","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1101\/gad.1550907","article-title":"Mechanisms of obesity-associated insulin resistance: many choices on the menu","volume":"21","author":"Qatanani","year":"2007","journal-title":"Genes Dev."},{"issue":"24","key":"10.1016\/j.phrs.2026.108192_bib136","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N. Engl. J. Med"},{"issue":"1","key":"10.1016\/j.phrs.2026.108192_bib137","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2337\/diacare.27.1.256","article-title":"Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association","volume":"27","author":"Nesto","year":"2004","journal-title":"Diabetes Care"},{"issue":"23","key":"10.1016\/j.phrs.2026.108192_bib138","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","volume":"355","author":"Kahn","year":"2006","journal-title":"N. Engl. J. Med"},{"issue":"8","key":"10.1016\/j.phrs.2026.108192_bib139","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1007\/s00125-010-1756-2","article-title":"Effects of the peroxisome proliferator-activated receptor (PPAR)-gamma agonist pioglitazone on renal and hormonal responses to salt in diabetic and hypertensive individuals","volume":"53","author":"Zanchi","year":"2010","journal-title":"Diabetologia"},{"issue":"10","key":"10.1016\/j.phrs.2026.108192_bib140","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1002\/pds.1470","article-title":"A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes","volume":"16","author":"Gerrits","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"12","key":"10.1016\/j.phrs.2026.108192_bib141","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.2337\/diacare.28.12.2984","article-title":"A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia: response to Goldberg et al","volume":"28","author":"Brunzell","year":"2005","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.phrs.2026.108192_bib142","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1161\/ATVBAHA.107.150193","article-title":"Pioglitazone stimulates apolipoprotein A-I production without affecting HDL removal in HepG2 cells: involvement of PPAR-alpha","volume":"27","author":"Qin","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108192_bib143","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/j.diabres.2015.09.009","article-title":"Safety and efficacy of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 52 weeks: an open-label extension study","volume":"110","author":"Kim","year":"2015","journal-title":"Diabetes Res Clin. Pr."},{"issue":"4","key":"10.1016\/j.phrs.2026.108192_bib144","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0092843","article-title":"Efficacy and safety of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 24-weeks: a multicenter, randomized, double-blind, parallel-group, placebo controlled trial","volume":"9","author":"Kim","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.phrs.2026.108192_bib145","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2023.102747","article-title":"Will lobeglitazone rival pioglitazone? A systematic review and critical appraisal","volume":"17","author":"Gangopadhyay","year":"2023","journal-title":"Diabetes Metab. Syndr."},{"issue":"11","key":"10.1016\/j.phrs.2026.108192_bib146","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1111\/j.1463-1326.2012.01631.x","article-title":"A 26-week, placebo- and pioglitazone-controlled monotherapy study of rivoglitazone in subjects with type 2 diabetes mellitus","volume":"14","author":"Chou","year":"2012","journal-title":"Diabetes Obes. Metab."},{"issue":"9","key":"10.1016\/j.phrs.2026.108192_bib147","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/j.1463-1326.2011.01411.x","article-title":"A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes","volume":"13","author":"Kong","year":"2011","journal-title":"Diabetes Obes. Metab."},{"issue":"1","key":"10.1016\/j.phrs.2026.108192_bib148","doi-asserted-by":"crossref","DOI":"10.1530\/JOE-24-0180","article-title":"Dual PPAR-alpha\/gamma enhances beta cell identity, preserving islet structure in HF-fed mice","volume":"264","author":"Fernandes-da-Silva","year":"2024","journal-title":"J. Endocrinol."},{"issue":"11","key":"10.1016\/j.phrs.2026.108192_bib149","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1177\/0091270003257230","article-title":"Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes","volume":"43","author":"Skrumsager","year":"2003","journal-title":"J. Clin. Pharm."},{"issue":"3","key":"10.1016\/j.phrs.2026.108192_bib150","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.lfs.2006.09.009","article-title":"Biochemical mechanism of insulin sensitization, lipid modulation and anti-atherogenic potential of PPAR alpha\/gamma dual agonist: Ragaglitazar","volume":"80","author":"Sharma","year":"2006","journal-title":"Life Sci."},{"issue":"6","key":"10.1016\/j.phrs.2026.108192_bib151","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.2337\/diacare.27.6.1324","article-title":"Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm","volume":"27","author":"Saad","year":"2004","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.phrs.2026.108192_bib152","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ahj.2015.03.021","article-title":"Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes","volume":"170","author":"Erdmann","year":"2015","journal-title":"Am. Heart J."},{"issue":"8","key":"10.1016\/j.phrs.2026.108192_bib153","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.clinthera.2005.08.005","article-title":"Muraglitazar, a dual (alpha\/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes","volume":"27","author":"Buse","year":"2005","journal-title":"Clin. Ther."},{"issue":"3","key":"10.1016\/j.phrs.2026.108192_bib154","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/1479164109336048","article-title":"Efficacy and safety of muraglitazar: a double-blind, 24-week, dose-ranging study in patients with type 2 diabetes","volume":"6","author":"Rubin","year":"2009","journal-title":"Diab Vasc. Dis. Res"},{"issue":"12","key":"10.1016\/j.phrs.2026.108192_bib155","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1185\/030079906X154169","article-title":"Effect of tesaglitazar, a dual PPAR alpha\/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial","volume":"22","author":"Goldstein","year":"2006","journal-title":"Curr. Med Res Opin."},{"issue":"3","key":"10.1016\/j.phrs.2026.108192_bib156","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3132\/dvdr.2007.042","article-title":"Group GS. Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulin-treated patients with type 2 diabetes","volume":"4","author":"Ratner","year":"2007","journal-title":"Diab Vasc. Dis. Res"},{"key":"10.1016\/j.phrs.2026.108192_bib157","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174032","article-title":"Effect of dual PPAR-alpha\/gamma agonist saroglitazar on diabetic retinopathy and oxygen-induced retinopathy","volume":"899","author":"Joharapurkar","year":"2021","journal-title":"Eur. J. Pharm."},{"issue":"1","key":"10.1016\/j.phrs.2026.108192_bib158","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-55466-3","article-title":"Effect of a Dual PPAR alpha\/gamma agonist on Insulin Sensitivity in Patients of Type 2 Diabetes with Hypertriglyceridemia- Randomized double-blind placebo-controlled trial","volume":"9","author":"Jain","year":"2019","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.phrs.2026.108192_bib159","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00592-020-01487-8","article-title":"Abrogation of postprandial triglyceridemia with dual PPAR alpha\/gamma agonist in type 2 diabetes mellitus: a randomized, placebo-controlled study","volume":"57","author":"Rastogi","year":"2020","journal-title":"Acta Diabetol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108192_bib160","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12933-020-01073-w","article-title":"Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study)","volume":"19","author":"Krishnappa","year":"2020","journal-title":"Cardiovasc Diabetol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108192_bib161","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.31843","article-title":"Saroglitazar, a PPAR-alpha\/gamma agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial","volume":"74","author":"Gawrieh","year":"2021","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.phrs.2026.108192_bib162","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.phrs.2026.108192_bib163","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.2337\/dc11-0093","article-title":"Effects of the new dual PPAR alpha\/delta agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism","volume":"34","author":"Cariou","year":"2011","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.phrs.2026.108192_bib164","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.2337\/dc12-2012","article-title":"Dual peroxisome proliferator-activated receptor alpha\/delta agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects","volume":"36","author":"Cariou","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.phrs.2026.108192_bib165","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/546548","article-title":"Vitro and In Vivo characterizations of chiglitazar, a newly identified PPAR Pan-Agonist","volume":"2012","author":"He","year":"2012","journal-title":"PPAR Res"},{"issue":"15","key":"10.1016\/j.phrs.2026.108192_bib166","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.scib.2021.03.019","article-title":"Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP)","volume":"66","author":"Ji","year":"2021","journal-title":"Sci. Bull."},{"issue":"15","key":"10.1016\/j.phrs.2026.108192_bib167","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.scib.2021.02.027","article-title":"Chiglitazar monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, phase 3 trial (CMAS)","volume":"66","author":"Jia","year":"2021","journal-title":"Sci. Bull."},{"issue":"6","key":"10.1016\/j.phrs.2026.108192_bib168","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jhep.2024.12.045","article-title":"Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD","volume":"82","author":"Barb","year":"2025","journal-title":"J. Hepatol."},{"issue":"17","key":"10.1016\/j.phrs.2026.108192_bib169","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the Pan-PPAR agonist Lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2026.108192_bib170","first-page":"5625","article-title":"Development of PPAR-agonist GW0742 as antidiabetic drug: study in animals","volume":"9","author":"Niu","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"issue":"5","key":"10.1016\/j.phrs.2026.108192_bib171","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/s41366-018-0011-7","article-title":"GQ-11: a new PPAR agonist improves obesity-induced metabolic alterations in LDLr(-\/-) mice","volume":"42","author":"Silva","year":"2018","journal-title":"Int J. Obes."},{"key":"10.1016\/j.phrs.2026.108192_bib172","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116220","article-title":"A pan-PPAR agonist E17241 ameliorates hyperglycemia and diabetic dyslipidemia in KKAy mice via up-regulating ABCA1 in islet, liver, and white adipose tissue","volume":"172","author":"Sheng","year":"2024","journal-title":"Biomed. Pharm."},{"issue":"6","key":"10.1016\/j.phrs.2026.108192_bib173","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1007\/s00125-016-3912-9","article-title":"Bavachinin, as a novel natural pan-PPAR agonist, exhibits unique synergistic effects with synthetic PPAR-gamma and PPAR-alpha agonists on carbohydrate and lipid metabolism in db\/db and diet-induced obese mice","volume":"59","author":"Feng","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.phrs.2026.108192_bib174","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105035","article-title":"ZLY032, the first-in-class dual FFA1\/PPARdelta agonist, improves glucolipid metabolism and alleviates hepatic fibrosis","volume":"159","author":"Li","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2026.108192_bib175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174244","article-title":"Synthesis, molecular docking, dynamic simulation and pharmacological characterization of potent multifunctional agent (dual GPR40-PPARgamma agonist) for the treatment of experimental type 2 diabetes","volume":"907","author":"Hidalgo-Figueroa","year":"2021","journal-title":"Eur. J. Pharm."},{"issue":"1","key":"10.1016\/j.phrs.2026.108192_bib176","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1124\/jpet.110.166504","article-title":"Bezafibrate mildly stimulates ketogenesis and fatty acid metabolism in hypertriglyceridemic subjects","volume":"334","author":"Tremblay-Mercier","year":"2010","journal-title":"J. Pharm. Exp. Ther."},{"issue":"10","key":"10.1016\/j.phrs.2026.108192_bib177","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1002\/oby.23874","article-title":"The tissue-specific metabolic effects of the PPARalpha agonist ciprofibrate in insulin-resistant male individuals: a double-blind, randomized, placebo-controlled crossover study","volume":"31","author":"de Wit-Verheggen","year":"2023","journal-title":"Obesity"},{"key":"10.1016\/j.phrs.2026.108192_bib178","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1475-2840-4-13","article-title":"Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]","volume":"4","author":"Scott","year":"2005","journal-title":"Cardiovasc Diabetol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108192_bib179","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1161\/01.ATV.0000154140.73570.00","article-title":"Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation","volume":"25","author":"Duez","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"6","key":"10.1016\/j.phrs.2026.108192_bib180","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1161\/ATVBAHA.108.178228","article-title":"Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate","volume":"29","author":"Taskinen","year":"2009","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"21","key":"10.1016\/j.phrs.2026.108192_bib181","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"N. Engl. J. Med"},{"issue":"6","key":"10.1016\/j.phrs.2026.108192_bib182","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1111\/jdi.12845","article-title":"Effects of a novel selective peroxisome proliferator-activated receptor-alpha modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance","volume":"9","author":"Matsuba","year":"2018","journal-title":"J. Diabetes Invest."},{"issue":"4","key":"10.1016\/j.phrs.2026.108192_bib183","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/dmrr.1187","article-title":"Efficacy and safety of the PPARgamma partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy","volume":"27","author":"Henriksen","year":"2011","journal-title":"Diabetes Metab. Res Rev."},{"issue":"10","key":"10.1016\/j.phrs.2026.108192_bib184","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.2337\/dc05-2445","article-title":"The effect of pioglitazone on the liver: role of adiponectin","volume":"29","author":"Gastaldelli","year":"2006","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.phrs.2026.108192_bib185","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.2337\/diacare.28.5.1145","article-title":"Effect of a peroxisome proliferator-activated receptor-gamma agonist on myocardial blood flow in type 2 diabetes","volume":"28","author":"McMahon","year":"2005","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.phrs.2026.108192_bib186","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00592-008-0054-7","article-title":"Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes","volume":"46","author":"Vijay","year":"2009","journal-title":"Acta Diabetol."},{"issue":"9493","key":"10.1016\/j.phrs.2026.108192_bib187","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.phrs.2026.108192_bib188","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1093\/eurheartj\/ehl079","article-title":"de Koning EJ, Visseren FL. TNF-alpha induces endothelial dysfunction in diabetic adults, an effect reversible by the PPAR-gamma agonist pioglitazone","volume":"27","author":"Martens","year":"2006","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.phrs.2026.108192_bib189","doi-asserted-by":"crossref","first-page":"376","DOI":"10.2337\/diacare.25.2.376","article-title":"Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients","volume":"25","author":"Yang","year":"2002","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.phrs.2026.108192_bib190","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1385\/ENDO:25:3:207","article-title":"Peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist increases plasma adiponectin levels in type 2 diabetic patients with proteinuria","volume":"25","author":"Yilmaz","year":"2004","journal-title":"Endocrine"},{"issue":"10","key":"10.1016\/j.phrs.2026.108192_bib191","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/j.metabol.2007.05.011","article-title":"Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease","volume":"56","author":"Yu","year":"2007","journal-title":"Metabolism"},{"issue":"7","key":"10.1016\/j.phrs.2026.108192_bib192","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2022.100233","article-title":"Saroglitazar is noninferior to fenofibrate in reducing triglyceride levels in hypertriglyceridemic patients in a randomized clinical trial","volume":"63","author":"Rodriguez-Gutierrez","year":"2022","journal-title":"J. Lipid Res."},{"issue":"2","key":"10.1016\/j.phrs.2026.108192_bib193","doi-asserted-by":"crossref","DOI":"10.1111\/1753-0407.13484","article-title":"Impact of chiglitazar on glycemic control in type 2 diabetic patients with metabolic syndrome and insulin resistance: a pooled data analysis from two phase III trials","volume":"16","author":"Ning","year":"2024","journal-title":"J. Diabetes"},{"issue":"5","key":"10.1016\/j.phrs.2026.108192_bib194","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2025.101680","article-title":"The impact of chiglitazar, a pan-PPAR agonist, on metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: a real-world study","volume":"51","author":"Tan","year":"2025","journal-title":"Diabetes Metab."},{"issue":"4","key":"10.1016\/j.phrs.2026.108192_bib195","doi-asserted-by":"crossref","first-page":"654","DOI":"10.4239\/wjd.v6.i4.654","article-title":"Role of peroxisome proliferator-activated receptors gene polymorphisms in type 2 diabetes and metabolic syndrome","volume":"6","author":"Dong","year":"2015","journal-title":"World J. Diabetes"},{"issue":"3","key":"10.1016\/j.phrs.2026.108192_bib196","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3392","article-title":"The Pro12Ala polymorphism of PPARgamma2 modulates beta cell function and failure to oral glucose-lowering drugs in patients with type 2 diabetes","volume":"37","author":"Masulli","year":"2021","journal-title":"Diabetes Metab. Res Rev."},{"issue":"8","key":"10.1016\/j.phrs.2026.108192_bib197","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.metabol.2009.10.030","article-title":"Common polymorphisms of the peroxisome proliferator-activated receptor-gamma (Pro12Ala) and peroxisome proliferator-activated receptor-gamma coactivator-1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitus","volume":"59","author":"Hsieh","year":"2010","journal-title":"Metabolism"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826001076?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826001076?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T22:31:10Z","timestamp":1778020270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661826001076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":197,"alternative-id":["S1043661826001076"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108192","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Roles of peroxisome proliferator-activated receptors (PPARs) in pancreatic metabolic diseases","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108192","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108192"}}